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1. Introduction
Cancer is perhaps the cruelest of deadly diseases in our era. So many factors play a role in
cancer and these features were characterized in 2011 as belonging to eight categories: evasion
of apoptosis, excessive growth signalling, insensitivity to anti-growth signals, maintained
angiogenesis, endless replicative potential, metastasis, reprogramming of energy metabolism
and avoidance of immune destruction. Types of cancer may be put in different categories (or
combinations of these) according to symptoms and pathogenesis, therefore revealing many
relationships.
Breast cancer is the most commonly diagnosed cancer type among women. There are similar‐
ities between breast and ovarian cancer such as similar mutations (tumor suppressors, proto-
oncoges), changes in hormone regulation and microenvironment, etc. In 2014, approximately
235,030 new cases are expected, and it is estimated that 40,430 deaths from breast cancer will
occur. Also, an estimated 21,980 new cases of ovarian cancer will be diagnosed in 2014, with
an estimated 14,270 deaths. Statistical results and similarities raise the question of whether
metastasis of breast cancer is related to the occurrence of ovarian cancer.
Several mutations in growth control genes can trigger the development of tumors in the body.
The specific causes of the mutations that lead to cancer are not fully known. Recent studies
have tried to uncover these unknown relationships between breast and ovarian cancer.
Understanding of the correlations between different types of cancers provide knowledge to
us about the disease process. Recent studies focus on common mutations, tumor micro-
environment, receptor inactivation, Trastuzumab resistance, etc. Thanks to these studies, new
therapeutic techniques have been developed such as using miRNA as therapeutic targets or
improvement of nanodrug delivery systems. Also, mathematical modeling has been used in
attempts to understand changes in metabolic pathways and metastasis.
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Briefly, understanding of the associations between breast and ovarian cancers provide
opportunities for the prevention of metastasis and allow development of new ways to cure
cancer.
2. Hereditary Breast and Ovarian Cancer (HBOC)
Despite intense studies about breast and ovarian cancer, these cancer types are the most
significant cause of death in women in our century. Recent studies have tried to identify
different types of mutations for certain genes and determine changes in copy numbers,
expression profiles, etc. by using high-throughput technologies [1]. Identifying variations
among breast and ovarian cancers will hopefully uncover associations between them, thus
possibly revealing methods for early disease screening and allow understanding of the
mechanism(s) of metastasis between these two cancer types.
Several studies have continued to find a common point for breast and ovarian cancer; all
studies have defined certain mutations in BRCA1/BRCA2 for these types of cancer. The
statistics show that 60-80% of BRCA1/BRCA2 gene mutation carriers will develop breast cancer
and 20-40% will develop ovarian cancer. Some cases of HBOC indicate a connection with
constitutive epimutations or other susceptibility genes such as several gene clusters including
the Fanconi anemia (FA) cluster (FANCD2, FANCA and FANCC), mismatch repair (MMR)
cluster (MLH1, MSH2, PMS1, PMS2 and MSH6), NA repair cluster (ATM, ATR and CHK1/2),
and tumor suppressor cluster (TP53, SKT11 and PTEN). If a patient does not have any
mutations in the BRCA genes but their cancer has a phenotype characteristic of those with
BRCA mutations and a dysfunction in a DNA repair system, it is known as ‘BRCAness’;[1]. In
conclusion,mutations that occur in some DNA repair mechanisms can increase the risk of
developing breast and ovarian cancer.
3. Identification of high penetrance of genes
The inactivation of BRCA1 and BRCA2 genes are germline mutations and trigger breast and
ovarian cancer. This phenomenon was confirmed by high throughput technologies used for
molecular diagnostics such as next generation sequencing (NGS). By using NGS, the DNA of
59 patients harbouring SNVs that include indels or large genomic rearrangements of BRCA1
or BRCA2 was analyzed. Also, 168 patients were used as blind study to compare NGS versus
Sanger sequencing or MLPA analyses of BRCA1 and BRCA2. Then, by using three different
capture methods, 708 consecutive patients were monitored. A total of 69 deleterious germline
alterations within BRCA1 and BRCA2, and 4 TP53 mutations were detected in 468 patients. In
addition to this, 36 variations that include either a premature codon stop or a splicing defect
among other genes were found (5/708 in CHEK2, 3/708 in RAD51C, 1/708 in RAD50, 7/708 in
PALB2, 3/708 in MRE11A, 5/708 in ATM, 3/708 in NBS1, 1/708 in CDH1, 3/468 in MSH2, 2/468
in PMS2, 1/708 in BARD1, 1/468 in PMS1 and 1/468 in MLH3). This study shows the efficiency
of NGS in performing molecular diagnosis of HBOC [2].
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In the past, full coding exon sequencing was challenging, because researchers had to analyse
dozens of coding genes using the traditional method of Sanger sequencing. It is a very time
consuming and labor intensive method. Thus, complicated genetic analysis was not possible.
However, new techniques have made such research easy. Also, parallel sequencing allows for
complicated genetic analysis in a short time. This technique is now reliable for genomic
research, but applying this in the clinic is still difficult due to the requirement of complex
equipment and highly trained staff [3]. In clinical applications, several library preparation
methods have been used to demonstrate a novel capture method. Targeting coding sequences
of genes have high coverage in every captured region. In order to streamline the number of
germline mutation variants, further whole exon sequencing studies and confirmations are
required in order to provide a gold standard for the investigation of germline variants.Nowa‐
days, clinical decisions that include molecular diagnoses have a significant impact on the
determination of treatments such as chemotherapy and prophylactic surgery. The association
between breast and ovarian cancer try to depend on high or low penetrance of genes that are
observable in both cancer types. The most common susceptibility genes in this field are BRCA1/
BRCA2. If any mutations are present in either of these genes, it translates to a 60-85% lifetime
risk of developing breast or ovarian cancer [4].
Germline mutations in BRCA1 and BRCA2 can be inherited by offspring and thus are known
as constitutional mutations. The mutations may have complete or partial gene deletions, large
insertions, duplications, splicing, frameshifts, missense and nonsense mutations. Insertions
and deletions may occur at the same position in the sequence and induce gene shuffling, which
in turn leads to abnormal gene structure, function,etc. The rate of these mutations changes
from population to population. According to data from the Breast Cancer Information Core
website, approximately 3500 mutations have been reported for both genes. For instance, female
breast cancer patients of Ashkenazi Jewish descent have a 10 – 12 % frequency of mutations
in these genes. Frequency of this mutation is higher than in the rest of the Caucasian popula‐
tion, because the female Ashkenazi Jewish population harbors ancient BRCA1 / BRCA 2
mutant alleles. The 5266dup, BRCA2999del5 and BRCA1delexon17 mutations have been
defined in some populations such as Slavic, Finnish, Icelandic and German [4].
In addition, the penetrance of mutations is important for genomic rearrangements to develop
into a detectable trait. Detection of high penetrance genes is easier than lower ones, because
they form symptoms and are always apparent in an individual carrying the allele. However,
several variations in low penetrance alleles are more common, and these low penetrance alleles
could increase risk to develop cancer and its progression [5]. Some researchers have focused
on identification of new genes to explain the missing heritability in BRCA negative cancer
patients, including targeted genes that may interact with BRCA pathways and proteins.
Nowadays, several studies have focused on finding these candidate genes and mutations using
NGS technologies. According to these studies, additional high penetrance alleles have been
found for breast/ovarian cancers; for instance, TP53, STK11,etc. Also, moderate penetrance
alleles such as PALB2, BRIP1, RAD51C have a role in cancer via their alteration in pathways
like Fanconi Anemia [6],[7]. In addition, ATM and CHEK2 have the same penetrance level and
are involved in the homologous recombination repair pathway [8]. Detection of mutations and
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penetrance within genes other than BRCA1 and BRCA2 has shed light on the genetic hetero‐
geneity of HBOC.
3.1. BRCA1 and BRCA2 genes
BRCA1 and BRCA2 genes are expressed in epithelial cells of breast and ovarian tissues. They
regulate the repair of some types of DNA damage and are involved in cell fate decision; if DNA
damage is too excessive and cannot be repaired efficiently, the cell will be directed to be
destroyed. Briefly, BRCA1 and BRCA2 genes are tumor supressor genes that are essential in
homologous recombination repair of double strand breaks [9], [10]. If any mutations or damage
occurs in BRCA1/BRCA2, DNA damage cannot be properly repaired and this increases the
risk of developing breast cancer [11]. However, BRCA1/2 are not oncogenes.They are normal
but their mutations are abnormal and cause formation of breast cancer. Chromosomal
arrangements may result from errors in the DNA damage response mechanism. It might lead
to genomic instability. If genomic rearrangements are large, they may escape detection. The
problem is that standard genetic testing is not capable of identifying large rearrangements and
therefore next generation and whole exon sequencing technologies must be used to detect these
gene modifications/changes [12].
Some studies have focused on solving the mechanisms of BRCA1 and BRCA2. According to
biochemical, genetic and cytological studies, the lack of BRCA1 results in cell death because
BRCA1 regulates stem/progenitor cell proliferation and differentiation. Apicobasal polarity is
regulated by BRCA1 and RHAMM (hyaluronan-mediated motility receptor), AURKA (aurora
kinase A) and TPX2 (microtubule-associated, homolog). This gene complex can change the
miotic spindle promoting activity of RHAMM which may control tumor progression. In
addition to this, BRCA1 binds and regulates AURKA which plays a role in the cell cycle as a
kinase and appears to be strongly involved in centrosome regulation. Therefore, variations of
the AURKA gene may contribute to breast cancer progression [13]. BRCA1 causes an accu‐
mulation of TPX2 and is required for mitotic spindle- pole assembly. Not only DNA damage
response and repair, but also cell differentiation requires the BRCA core complex proteins for
functional integrity.
BRCA1 interacting protein or complex Function of interactingprotein
Interacting
domain(a.a. residues) Ref.
RAD51 DSB repair Exon 11 (758-1064) [14]
RAD50 DSB repair Exon 11(341- 748) [15]
BRCA2 DSB repair BRCT domain(1314-1863) [14]
BASC (QTM,BLM,MSH2,MSH6,MLH1,RCF) Mismatch repair BRCA part of complex [16]
p53 Transcription Factor,tumor supressor
Exon 11 and BRCT
domain (224 – 500 and
1760-1863)
[17], [18]
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BRCA1 interacting protein or complex Function of interactingprotein
Interacting
domain(a.a. residues) Ref.
pRB Cell cycle regulator
Exon 11 and BRCT
domain (304-394 and
15336-1863)
[19]
c-Myc TF,oncogene
N-terminus and
exon11
(175-303 and 433-511)
[20]
ZBRK1 TF,represses GADD45 Exon 11 (341-748) [21]
ATF TF RING (1-101) [22]
STAT1 Signal transducer,TF Exon 11(502-802) [23]
E2F TF,cell cycle regulator N-terminus (1-76) [24]
RNA Pol II holoenzyme *(RPH) Transcription BRCT domain(1650-1800) [25], [26]
RNA helicase A Component of RPH BRCT domain(1650-1800) [27]
Estrogen receptor Ligand responsive TF N-terminus (1-300) [28, 29]
Androgen receptor Ligand responsive TF
Exon 11;BRCT
domain (758-1064 and
1314-1863)
[30]
CtIP Transcriptional co-repressor
BRCT domain
(1651-1863) [31, 32]
p300/CBP Transcriptionalcoactivator
RING and BRCT
domain (1-303 and
1314-1863)
[33]
HDAC1 and 2 Histone deacetylation;chromation remodeling
BRCT domain
(1563 - 1863) [34]
Centrosome (p53,Prb,Nm23) Chromosomesegregation
*BRCA1 part of the
complex [35]
BRAP2 Cytoplasmic retention NLS (303-701) [36]
Vasolin- containing protein, VCP ATPase Exon 11 ( 303- 625) [37]
BARD1 Ubiquitination RING (1-101) [38]
BAP1 Deubiquitinatingenzyme RING (1-100) [39]
Importin α Nuclear transport NLS (303-701) [40]
BRCA2 interacting protein or complex -
Interacting domain
(a.a. residues) on
BRCA2
[41]
Table 1. BRCA interacting proteins
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Many biochemical studies have shed light on a multitude of proteins with defined interactions
with BRCA1 and BRCA2. These proteins are involved in control mechanisms of DNA double
strand breaks. Within several minutes after damage, H2AX, a member of the histone H2A
family of proteins, becomes phosphorylated and foci form at the site of DNA double strand
breaks [42]. BRCA1 is recruited with this area within several hours. Subsequently, RAD50 and
RAD51 interact with the strand breaks. This situation shows that BRCA1 and H2AX can initiate
repair mechanisms of local chromatin structure, thus DNA repair proteins can access damaged
sites.
If BRCA1 and BRCA2 genes are absent from the cell, chromosomal abnormalities, breaks,
aneuploidy and centrosome amplification occurs. The pathogenic tumor formation in breast
and ovarian tissue may depend on chromosomal instability that is the result of deficiency of
BRCA1 and BRCA2 genes. In order to reveal this relation, researchers monitored sporadic
breast and ovarian tumors. 50 – 70 % of them were found to have lost an BRCA1 allele and 30
– 50 % were found to have lost an BRCA2 allele [43],[44].
Genomic instability of BRCA1 and BRCA2 genes result from the repetitive DNA elements that
are of high density. 42% of BRCA1 consists of Alu sequences and 5% non-Alu repeats. The
genomic region of BRCA2 consists of 47% repetitive DNA [45]. BRCA1 and BRCA2 are rare
genes that include high density repetitive DNA regions. Multiple diseases are mediated by
genetic rearrangements of Alu sequences. According to the given density of repeat elements
in BRCA1 and BRCA2, careful analysis of these genes can reveal the risk of breast and ovarian
cancer due to these susceptibility genes.
The source of the large deletions depends on repetitive regions on genes. One mechanism that
manages the large deletions observed around the BRCA1 and BRCA2 that are inherited and
sporadic tumors in breast and ovarian cancer (Figure1). These repeat regions may be far apart
from the linear DNA but physically close in the nucleus. For instance, if a chromosome break
occurs near a replication fork during replication, it might be repaired by HR to a replication
fork at a nearby anchorage point.
3.2. Association between DNA damage and BRCA1-BRCA2 genes
Double strand breaks such as exposure to ionizing radiation or certain kinds of DNA-
damaging agents. Genetic defects in DNA damage response genes and/or down-regulation of
the DNA repair mechanisms induces genomic instability, and this can lead to carcinogenesis
[46]. Among the many DNA repair pathways available in mammalian cells are homologous
repair, non-homologous end-joining and single-strand annealing [47]. There are several ways
that cells can repair double strand breaks. A number of signaling pathways are involved in
the detection of DSBs and regulate DNA repair or apoptotic cell death. The main DNA damage
recognition molecule is ATM [48], a checkpoint kinase that phosphorylates a number of
proteins in response to DNA damage, including p53 and BRCA1 [Figure2].
p53 plays a critical role in preventing cancer development. Generally, p53 gene is mutated in
cancer tissue, so it cannot protect the genetic integrity of cells. In physiological conditions, p53
is activated when DNA damage occurs. The failure of DNA damage response results in p53
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mediated cell apoptosis [49]. Several mechanisms regulate p53 activity. p21WAF-1 has been
shown to play an important role in both p53-dependent [50] and -independent pathways [51].
p21WAF-1 prevents cell cycle progression via interaction with the cyclin-dependent kinase
(CDK) complex. Therefore, p53 plays a role in the most important part of providing stability
to the genome by using cell cycle checkpoints, DNA repair and apoptosis.
BRCA1 also involves a gold standard for a tumor suppressor gene that is needed to prevent
cancer development and progression. BRCA1 / BRCA2 related breast and ovarian cancers are
have defects in a DNA repair pathway [52]. Studies have shed light on the functional roles of
BRCA1/BRCA2 genes in DNA repair, cell cycle checkpoints and DNA damage signaling
pathways [53]. BRCA1 interacts with several cyclins and CDKs, triggers the activation of the
CDK inhibitor, p21WAF-1, and p53, thus it can control the cell cycle. The main function of
BRCA1 depends on its phosphorylation status, so if the gene becomes hyper-phosphorylated
following any damage or exposure to DNA damaging agents, it becomes non-functional[54].
Also, BRCA1 and BRCA2 genes are not only responsible for DNA damage response but also
their proteins interact with the estrogen and androgen receptors [55]. These genes inhibit
Figure 1. A mechanism for the formation of deletion by loss of a chromatin loop at different stages. Deletions of phase
1 occur in S phase, when the same repetitive sequences are physically brought together by MAR (blue ellipse). Breaks
in DNA, and their repair, might lead to deletion of a chromatin loop (red). Deletions of type 2 and 3 occur by the same
mechanism but occur later during DNA synthesis in the replication cycle. (Adapted from Piri et al [11])
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estrogen receptor-α activity and stimulate androgen receptors. In this way, BRCA1 mutations
are associated with hormone responsive cancer. In other words, the cancer risk of BRCA1
mutation carriers will increase via hormonal factors.
3.3. Association of estrogens — Estrogen receptors with BRCA genes
Estrogen, progesterone and androgen hormones control the initiation of carcinogenesis by
using special hormone receptors. Moreover, hormonal therapies frequently regulate hormone-
mediated diseases such as cancer. A number of candidate genes have been identified as
biomarkers for ovarian and breast cancers [56].
Frequently, damage in the DNA repair system induce growth arrest and cell death. BRCA
deficient mice die in the early stages of embryogenesis. The first question that arises is why
BRCA deficient breast or ovarian epithelial cells develop tumors instead of undergoing
apoptosis? What is special to breast and ovarian epithelial cells that allows them to escape
apoptosis or response to the DNA damage response system? Finally, how are BRCA1 and
BRCA2 genes associated with estrogen levels?
The transition of the hormone independence induces the progression of breast and ovarian
cancer because of DNA repair defects. The estrogen-bound receptor dimerizes and associates
with chromatin. The estrogen response elements that are present on a DNA sequence motif
bind directly to the receptor dimers. There are two kind of estrogen receptors:estrogen
receptor-α and estrogen receptor-β. Estrogen receptor-α plays a role in proliferation, and the
activation of estrogen receptor-β controls apoptosis [57]. An increase in estrogen receptor-β
Figure 2. Schematic representation and overview of the DNA repair and checkpoint regulation of cell cycle
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levels might be related with a reduction in breast cancer risk [58]. Estrogen receptor-β may
prevent cellular proliferation by action opposite to that of estrogen receptor-α.
Figure 3. Schematic representation of interaction between BRCA1 and estrogen receptor (ER)-α
A woman exposed to estrogen either endogenously or exogenously, has an increased risk of
developing breast or ovarian cancer. BRCA1 and BRCA2 expression levels are highest during
pregnancy and puberty, when estrogen levels are increased [59].
If estrogens triggers cell proliferation [60], increased estrogens promotes the probability of
developing random genetic rearrangements and errors. Metabolic processes produce reactive
oxygen species (ROS) that cause oxidative damage to genomic DNA. In addition, some
hormone oxidative metabolites catalyzed by cytochrome p450 enzymes can form unstable
adducts in DNA which then leads to mutations [61].
Figure 4. Connection of the hormone endocrine, immune, DNA damage and DNA repair systems in cancer
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A long period of exposure to estrogen is strongly associated with an increased risk of devel‐
oping breast and ovarian cancer. However, activation of DNA damage response mechanisms
may be triggered via androgen signaling [62]. The estrogen receptor-mediated pathways are
inhibited by BRCA1 and BRCA2 proteins which function as a suppressor in mammary
epithelial cell proliferation. Also, the estrogen receptor complex regulates the transcription of
BRCA1 and BRCA2 under the condition of estrogen stimulation. In addition, estrogens are not
only essential for mammary growth and differentiation, but also enhance the activity of the
p53 tumor suppressor protein [63].
4. Biomarkers in breast and ovarian cancer
4.1. The KRAS-variant (A germline microRNA binding site-disrupting variant)
Cancer susceptibility genes increase the risk of malignancy as a result of mutations in tumor
suppressor or oncogenes that control different pathways. The KRAS variants are active at the
site of the 3’-untranslated region of the complementary site of let-7 miRNA. miRNAs are 22-
nucleotide long noncoding RNAs that are conserved regions. They are a novel class of
oncogenes and tumor supressors that are upregulated in cancers [64]. Recent studies showed
that SNPs that are present in miRNA binding sites can be powerful markers of cancer risk [65].
Ratner et al. reported that KRAS is associated with 61% of cases of breast and ovarian cancer
syndrome. In another study, KRAS variants were observed to be increased within women with
triple-negative breast cancer [66]. A study at Yale University, involving 58 hereditary breast
and ovarian syndrome patients tested for the presence of the KRAS variant. The KRAS-variant
was identified in 60% of HBOC patients who lacked BRCA1 or BRCA2 mutations. These
findings strongly support the hypothesis that the KRAS-variant is a genetic marker of an
increased risk of developing ovarian cancer[67].
The KRAS variant might be a new biomarker for breast and ovarian cancer. Therefore,
preventing or identifying cancer in early steps may be possible by using this biomarker.
4.2. Flap Endonuclease 1 (FEN1) as a biomarker in breast and ovarian cancer
FEN1 is a kind of flap structure endonuclease that is critical for DNA repair processing. It is
involved in long patch base excision repair (LP-BER) and Okazaki fragment maturation during
replication. In addition, it plays a role in rescue delayed in replication forks, managing of
telomere stability and apoptotic formation of DNA [68] [69]. Fen1 is also a main actor in
posttranslational modifications such as acetylation, phosphorylation, sumoylation, methyla‐
tion and ubiquitylation which control nuclease activities [68] [69].
FEN1 has a role in tumor formation. A FEN1 E160D mutant mouse model shows alteration in
DNA repair [70] [71]. These changes trigger an increased frequency of cancer development.
Polymorphic variations of FEN1 in humans may be associated with high frequency cancer
susceptibility [72, 73].
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FEN1 has an impact on breast tumors. It affects BRCA1, PARP1, XRCC1 and TOP2A genes.
There is an association between high FEN1 and ATM expression. FEN1 may regulate the ER-
induced transcriptional response with interaction of estrogen response elements [74]. There is
a complex network between ER, FEN1 and ATM in breast cancer cells. Similarly, in ovarian
cancer, FEN1 expression is linked to an aggressive phenotype and poor survival [75]. Abdel-
Fatah et al. demonstrated that FEN1 overexpression is associated with an aggressive pheno‐
type and poor survival in breast and ovarian cancer.
5. Conclusion
Despite the more intense studies about breast and ovarian cancer, these cancer types are the
most significant cause of death in women in our century. Recent studies have tried to stream‐
line the number of mutations for specific genes and identify changes in copy number, expres‐
sion profiles, etc. by using high-throughput technologies for identification of variations.
Identification of all kinds of variations will uncover associations between breast and ovarian
cancer, and thus reveal potential disease screening methods and provide an understanding of
the mechanism of metastasis between these two cancer types. In this chapter, we aimed to
gather the current knowledge about susceptibility genes BRCA1 and BRCA2 which are highly
connected with breast and ovarian cancer. Also, mechanisms and hormones (estrogen) that
induce cancer associated with BRCA1/BRCA2 have been discussed. Finally, new biomarkers
including FEN1 and KRAS for breast and ovarian cancer have been discussed.
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